Kyocera Corporation (President: Hideo Tanimoto, hereafter 'Kyocera') today announced that it has entered a license and collaboration agreement with Sydney, Australia-based Regeneus Ltd. (CEO: Leo Lee, hereafter 'Regeneus') for exclusive rights in Japan to develop, produce, and commercialize Regeneus's unique cell-preparation1 technology as a regenerative medical product for treating patients with knee osteoarthritis.
The technology licensed from Regeneus enables allogeneic mesenchymal stem cells2 to be formulated into a cell preparation that can be administered to patients. Regeneus has completed an early clinical test in Australia for patients suffering from knee osteoarthritis, with promising results.
An estimated 25 million people in Japan exhibit osteoarthritic conditions in the knee, and approximately 8 million are fully symptomatic.3 About 1.4 million in total are currently receiving treatment for arthrosis, including knee osteoarthritis, and the number increases yearly.4 Kyocera aims to develop and commercialize the cell-preparation technology as a new product for treating these patients.
Kyocera is committed to developing new technologies and products that contribute to human health and well-being. The company is currently expanding its medical and healthcare R&D activities, which include orthopedic joint replacement systems and dental implants developed through its proprietary materials and surface-processing technologies, as well as regenerative medicine and presymptomatic treatments.
Regeneus Ltd (ASX:RGS) is a Sydney-based regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus.
(C) 2020 Electronic News Publishing, source ENP Newswire